A Vaccine Antigen Master File (VAMF) is the component of a vaccine <a href="https://www.ddregpharma.com/what-is-marketing-authorization-application" rel="noopener noreferrer" target="_blank">Marketing Authorisation Application</a> (MAA) that specifically addresses the active substance. It includes detailed information on the starting materials and reagents, the manufacturing process, specifications and routine quality controls, stability data, and viral safety aspects of the vaccine antigen. It does not, however, cover information related to the formulation process or subsequent downstream production steps. It is submitted and evaluated as a standalone file, separate from the Marketing Authorisation Application (MAA), and can be cross-referenced in one or more MAAs by the same or different <a href="https://www.ddregpharma.com/what-is-a-marketing-authorization-holder" rel="noopener noreferrer" target="_blank">Marketing Authorisation Holders</a> (MAHs).What is the significance of Vaccine Antigen Master File (VAMF)?The VAMF system was introduced to streamline regulatory processes and ensure consistency in the evaluation of vaccine antigens.<ul><li style="font-size: 16px">Avoids duplication: Instead of re-submitting identical antigen data in every Marketing Authorisation Application (MAA), a VAMF allows a single, centrally-evaluated dataset to be cross-referenced by multiple dossiers.</li><li style="font-size: 16px">Harmonises data: Ensures that all vaccines containing the same antigen rely on identical, up-to-date quality information, reducing discrepancies between national and centralised procedures.</li><li style="font-size: 16px">Speed variations: Once certified, any variations (e.g., process improvements, site changes) to that antigen need only be submitted once under the VAMF system, and the resulting certificate automatically applies to all linked MAAs.</li><li style="font-size: 16px">Centralised Certification: The EMA conducts a first-step, centralised evaluation of the VAMF dossier. Upon a positive assessment, the EMA issues a VAMF Certification, confirming that the antigen data complies with regulatory requirements, and this certification is valid across the EU/EEA.</li></ul>What are the key features of Vaccine Antigen Master File (VAMF)?zAn application for a VAMF may be submitted as follows:<ul><li style="font-size: 16px">Trigger 1: As part of a new centralised MAA (certification is embedded in MAA assessment).</li><li style="font-size: 16px">Trigger 2: Linked to a new MAA via the Mutual Recognition (MR) procedure.</li><li style="font-size: 16px">Trigger 3: Linked to a purely national procedure if the antigen has previously undergone a community procedure.</li><li style="font-size: 16px">Trigger 4: Stand-alone certification initiated by the MAH for existing authorised vaccines.</li></ul>The evaluation cycle follows a 90-day timeline for all VAMF certification applications following triggers 2, 3 and 4.<h3>What are the challenges associated with Vaccine Antigen Master File (VAMF)?</h3><ul><li style="font-size: 16px">Ongoing Variations: If there are pending variations to the vaccine antigen in any related MA, VAMF certification cannot begin. Agencies must carefully manage submission calendars to avoid conflict.</li><li style="font-size: 16px">Cross-Referencing and Access Rights: Cross-referencing the VAMF requires explicit authorization from the VAMF holder. If documentation (e.g., Letters of Access) is missing or late, agencies risk validation failure.</li><li style="font-size: 16px">Technical Limitations with eCTD: Integrating VAMF content or cross-referencing within eCTD structure can be technically tricky.</li><li style="font-size: 16px">Synchronisation with MAA Timelines: When the VAMF certification is part of a new MAA (Trigger 1), its evaluation must be completed in time to support CPMP opinion. This puts pressure on project planning and buffer timelines.</li></ul><h4>DDReg’s capability-</h4>Navigating the complexities of Vaccine Antigen Master File (VAMF) certification demands precise regulatory planning, technical accuracy, and deep coordination across stakeholders. At DDReg, we specialise in end-to-end VAMF support. Our experienced <a href="https://www.ddregpharma.com/solutions/regulatory-affairs" rel="noopener noreferrer" target="_blank">regulatory services professionals</a> ensure compliance with EMA guidelines and seamless alignment with centralised, mutual recognition, or national procedures.

Vaccine Antigen Master File (VAMF) is a document that provides information on materials, processes, specifications, and safety used in vaccine development.

What is Vaccine Antigen Master File (VAMF)?